Background: Antithrombotic therapy is recommended in atrial fibrillation (AF) patients due to high risk of stroke. However, antithrombotic therapy is often underutilized due to adverse effects and limited data available in Indian population. Aims: Primary objective was to study usage pattern of antiplatelet and anticoagulant drugs in AF patients. Secondary objective was to assess the risk of stroke and compare usage pattern of antithrombotic drugs in non-valvular atrial fibrillation (NVAF) patients with application of CHADS2 and CHA2DS2-VASc score. Materials and Methods: A prospective and observational study was conducted in outpatient department for period of one year in patients > 35 years of either gender diagnosed with AF due to any established cause. CHADS2 and CHA2DS2-VASc score were used to assess risk of stroke among NVAF patients. Results: 111 patients diagnosed with AF (mean age 54 years; 54.96% female) were analyzed and out of these, 78 patients were valvular AF patients and 33 were NVAF patients. Anticoagulants were predominantly prescribed in 60 valvular AF patients. Out of 33 NVAF patients, 19 (57.57%) patients had CHADS2 score 1 while as per CHA2DS2-VASc score 28 (84.84%) patients had score ≥ 2. Out of 33 NVAF patients, 15 (45.45%) patients were prescribed warfarin, aspirin in 12 (36.36%) patients and no antithrombotic therapy in 6 (18.18%) patients. Conclusion: Oral anticoagulant drugs are most commonly prescribed antithrombotic drugs in valvular AF and NVAF patients for stroke prevention. CHADS2 and CHA2DS2-VASc score are easy, simple schemes to assess stroke risk in NVAF patients and helps physicians and patients to choose most suitable antithrombotic therapy.

No abstract

No abstract

Objective: To evaluate the usage pattern of antithrombotic in patients suffering from deep vein thrombosis (DVT) in a tertiary care teaching hospital. Methods: It was an observational, prospective and single centre study carried out over period of 18 months among the indoor patients suffering from DVT in department of Surgery, Orthopedics and Neurosurgery at a tertiary care teaching hospital. Results: Out of 26,687 indoor patients assessed for eligibility, only 32 (0.12%) patients were of DVT. Out of 32 patients of DVT, all the patients were prescribed anticoagulant drug whereas, 4 patients were prescribed both antiplatelet and anticoagulant. Only 2 patients were given aspirin as a single drug. No modification of antiplatelet therapy was observed. None of DVT patients had contraindication to use of anticoagulants. Only 4 patients developed bleeding during follow up. Conclusion: DVT treatment is very important and antithrombotic therapy is mainstay of treatment among patients of DVT. All patients of DVT received adequate antithrombotic therapy. Warfarin was most commonly used anticoagulant for DVT treatment. Key words: Antithrombotic, Deep vein thrombosis, Drug utilization. Key message: Warfarin and enoxaparin are most commonly prescribed anticoagulants for treatment of DVT. Risk and benefits should be considered in the decision for antithrombotic treatment with anticoagulants. With proper antithrombotic guidelines, morbidity and mortality due to DVT or complications of DVT can be prevented to improve quality of life (QOL).